Cancer medicine · 2026
Efficacy of Topical Beta-Blockers in Managing Epidermal Growth Factor Receptor Inhibitor-Related Paronychia and Pyogenic Granuloma-Like Lesion: A Systematic Review and Meta-Analysis.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chan Po-Kai, Yen Wei-Ting, Chen Po-Huang
Аннотация
INTRODUCTION: Epidermal growth factor receptor (EGFR) inhibitors, including tyrosine kinase inhibitors (TKIs), are associated with paronychia and pyogenic granuloma-like lesions (PGLs) that significantly impair patients' quality of life. Topical beta-blockers emerge as a non-invasive and promising therapy for such adverse events. This meta-analysis evaluated the efficacy of topical beta-blockers for EGFR inhibitor-induced paronychia and PGLs.
METHOD: In accordance with the PRISMA 2020 guidelines, multiple databases were searched for relevant studies. The primary outcomes were overall response rate (ORR) and complete response rate (CRR) within 1 month. Secondary outcomes included safety outcomes and subgroup analyses, while meta-regression was performed to assess the moderating effects of baseline characteristics. R programming was used for analysis and plotting.
RESULTS: Six studies involving 96 patients were included. Topical beta-blocker yielded a high pooled ORR of 0.94 (confidence interval, CI 0.81-1.00, I2 = 69%) and CRR of 0.34 (CI 0.15-0.57, I2 = 76%) within 1 month. Despite no significant between-group differences, lower CRR were found in lung cancer (0.35, 95% CI [0.12, 0.60]) and solution formation subgroup (0.30, 95% CI [0.06, 0.62]). Meta-regression identified negative trends in CRRs for female patients and TKI users (p < 0.1). No adverse event was reported.
CONCLUSION: Our research concluded that topical beta-blockers may be a well-tolerated and beneficial option for managing EGFR inhibitor-induced paronychia and PGL. Additional and large-scale randomized controlled trials are necessary to confirm these findings, standardize treatment protocols, and evaluate long-term effectiveness.
METHOD: In accordance with the PRISMA 2020 guidelines, multiple databases were searched for relevant studies. The primary outcomes were overall response rate (ORR) and complete response rate (CRR) within 1 month. Secondary outcomes included safety outcomes and subgroup analyses, while meta-regression was performed to assess the moderating effects of baseline characteristics. R programming was used for analysis and plotting.
RESULTS: Six studies involving 96 patients were included. Topical beta-blocker yielded a high pooled ORR of 0.94 (confidence interval, CI 0.81-1.00, I2 = 69%) and CRR of 0.34 (CI 0.15-0.57, I2 = 76%) within 1 month. Despite no significant between-group differences, lower CRR were found in lung cancer (0.35, 95% CI [0.12, 0.60]) and solution formation subgroup (0.30, 95% CI [0.06, 0.62]). Meta-regression identified negative trends in CRRs for female patients and TKI users (p < 0.1). No adverse event was reported.
CONCLUSION: Our research concluded that topical beta-blockers may be a well-tolerated and beneficial option for managing EGFR inhibitor-induced paronychia and PGL. Additional and large-scale randomized controlled trials are necessary to confirm these findings, standardize treatment protocols, and evaluate long-term effectiveness.